Published in

BMJ Publishing Group, International Journal of Gynecological Cancer, 4(13), p. 413-418, 2003

DOI: 10.1136/ijgc-00009577-200307000-00003

BMJ Publishing Group, International Journal of Gynecological Cancer, 4(13), p. 413-418

DOI: 10.1046/j.1525-1438.2003.13318.x

Links

Tools

Export citation

Search in Google Scholar

Pseudomyxoma peritonei: The 'controversial' disease

Journal article published in 2003 by E. Galani, G. M. Marx, C. B. Steer ORCID, G. Culora, P. G. Harper
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Pseudomyxoma peritonei (PMP) is a rare disease that is characterized by a large amount of mucinous ascites with peritoneal and omental implants. The etiology of the disease remains unclear. Histologically, two main categories have been described: disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA). It is commonly diagnosed incidentally at laparotomy. Most investigators agree that radical surgical debulking and appendectomy are the cornerstone of treatment, but the optimal management of the disease remains controversial. The role of intraoperative and intraperitoneal chemotherapy has been evaluated by a number of authors. The clinical outcomes vary widely between the benign and the malignant forms and between the different treatment modalities. We discuss the pathology, origin, clinical presentation, diagnosis, treatment, and prognosis of PMP.